Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combination products: adapting the EU regulatory framework to reality

This article was originally published in SRA

Executive Summary

Shayesteh Fürst-Ladani says that EU rules on combination healthcare products must avoid duplication of evidence gathering and of regulatory submissions and provide opportunities for early dialogue between stakeholders.

You may also be interested in...

Succeeding in Switzerland's regulatory environment for pharma - similarities and differences compared with the EU

Shayesteh Fürst-Ladani highlights critical differences between the Swiss and EU regulatory systems that drug manufacturers should be aware of and discusses how Swissmedic plans to shorten its review timelines.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts